Scientist

Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

Position:

Nurix Therapeutics is seeking a Scientist to lead bioanalytical strategies supporting the discovery and development of next-generation degrader antibody conjugates (DACs). This role will focus on LC-MS/MS and hybrid assay strategies for quantitative and qualitative analysis of complex bioconjugates across in vitro and in vivo studies to understand DAC pharmacokinetics, pharmacodynamics, and biotransformation.

The successful candidate will operate at the interface of small and large molecule bioanalysis, and will contribute to assay development, method qualification, and execution, applying advanced LC-MS/MS and hybrid approaches to support in vitro and in vivo studies across discovery and early development

**Key Responsibilities:
**

• Lead the development, qualification, and execution of bioanalytical methods for DAC modalities, including intact conjugates, total antibody, conjugated payload, and released degrader species in complex biological matrices.
• Design and implement LC-MS/MS-based workflows using Sciex platforms for sensitive and selective quantitation of small molecule payloads, linker-derived species, and catabolites
• Apply high-resolution mass spectrometry platforms for DAC characterization and metabolite identification
• Develop hybrid LBA–LC-MS/MS strategies to address challenges in conjugate quantitation and differentiation of molecular species.
• Design, execute and interpret in vitro studies, including plasma and lysosomal stability, linker cleavage kinetics, protease-mediated processing, and degradation assays.
• Lead bioanalytical support for in vivo studies, including PK, tissue distribution, and tumor exposure in preclinical species integrating DAC components to inform exposure-response relationships.
• Characterize biotransformation pathways of DACs, including identification of linker cleavage products, payload metabolites, and antibody modifications.